department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Fruzaqla · pharmadog

pharmadog
drugs
Fruzaqla

drug

patient view →

fruquintinib

Marketedupdated 2mo ago

by Takeda Pharmaceuticals USA Inc

Approved

community read0 votes

all catalysts(1)

phase 2 initiation · 1

phase 2 initiation

Jiangsu Hengrui Pharmaceuticals Co Ltd — fruquintinib (Phase II Trial Initiation)

News(0)

no news has mentioned this drug yet

brand

Fruzaqla

generic

fruquintinib

indication

Metastatic Colorectal Cancer

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 12m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

May 9, 2028

~1.8 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (8)

Sep 7, 2035compositionUS 10519142
Sep 7, 2035compositionUS 10519142
Sep 7, 2035method-of-use (U-3753)US 11046674
Sep 7, 2035method-of-use (U-3753)US 11046674
Mar 23, 2032compositionUS 7829574
Mar 23, 2032compositionUS 7829574
May 9, 2028method-of-use (U-3753)US 82120331.8y
May 9, 2028method-of-use (U-3753)US 82120331.8y

FDA exclusivities (2)

Nov 8, 2028NCENew Chemical Entity (5y)2.3y
Nov 8, 2028NCENew Chemical Entity (5y)2.3y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 3

tagOncology2 co-mentions · 1 sources
companyJiangsu Hengrui Pharmaceuticals Co Ltd1 co-mentions · 1 sources
tagColorectal Cancer1 co-mentions · 1 sources

Trials studying fruquintinib

phase2A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancernot yet recruitingn=68
phase3Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignanciesactive not recruitingn=404
phase2Trial of 5-Fluorouracil (5FU)-Based Therapy in Combination With Fruquintinib in Patients With Locally Advanced Unresectable or Metastatic Colorectal Cancerrecruitingn=50
phase2A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.recruitingn=90
phase2SHR-3821 in Advanced Colorectal Cancer: an Exploratory Studynot yet recruitingn=12
phase2A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapyrecruitingn=20
phase2A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line Treatment for Metastatic Colorectal Cancernot yet recruitingn=60
phase3A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugsnot yet recruitingn=142

more trials →